US top court denies Teva stay in Copaxone patent fight

WASHINGTON - US Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.
The decision could help pave the way for generic competitors to go on the market as soon as next month.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy